Investigation of purification process stresses on erythropoietin peptide mapping profile

Sepahi, Mina; Kaghazian, Hooman; Hadadian, Shahin; Norouzian, Dariush

Investigation of purification process stresses on erythropoietin peptide mapping profile

Authors

¹ Department of Recombinanit Biopharmaceutical Production, Pasteur Institute of Iran, Karaj, Iran

² Department of Quality Control, Pasteur Institute of Iran, Karaj, Iran

³ Department of Pilot Biotechnology, Pasteur Institute of Iran, Tehran, Iran

Abstract

Background: Full compliance of recombinant protein peptide mapping chromatogram with the standard reference material, is one of the most basic quality control tests of biopharmaceuticals. Changing a single amino acid substitution or side chain diversity for a given peptide changes protein hydrophobicity and causes peak shape or retention time alteration in a peptide mapping assay. In this work, the effect of different stresses during the recombinant erythropoietin (EPO) purification process, including pH 4, pH 5, and room temperature were checked on product peptide mapping results.
Materials and Methods: Cell culture harvest was purified under stress by different chromatographic techniques consisting of gel filtration, anionic ion exchange, concentration by ultrafiltration, and high resolution size exclusion chromatography. To induce more pH stresses, the purified EPO was exposed to pH stress 4 and 5 by exchanging buffer by a 10 KDa dialysis sac overnight. The effects of temperature and partial deglycosylation (acid hydrolysis) on purified EPO were also studied by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and peptide mapping analysis. Removal of sialic acid by mild hydrolysis was performed by exposure to two molar acetic acid at 80°C for 3 h.
Results: No significant effect was observed between intact and stressed erythropoietin peptide mapping profiles and SDS-PAGE results. To validate the sensibility of the technique, erythropoietin was partially acid hydrolyzed and significant changes in the chromatographic peptide map of the intact form and a reduction on its molecular weight were detected, which indicates some partial deglycosylation.
Conclusions: Purification process does not alter the peptide mapping profile and purification process stresses are not the cause of peptide mapping noncompliance.

Keywords

References

1.	Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: An update. Pharm Res 2010;27:544-75.
2.	Rader R. FDA Biopharmaceutical Product Approvals and Trends. Biotechnology Information Institute. Available from: http://www.biopharma.com/approvals_2011.html. [Last accessed on 2012 Jan 16].
3.	Atkins HL, Broudy VC, Papayannopoulou T. Characterization of the structure of the erythropoietin receptor by ligand blotting. Blood 1991;77:2577-82.
4.	Kaur I, Pillai MG, Singh N. An overview of biologics: Science behind protein therapeutics. J Proteins Proteomics 2012;3:229-37.
5.	de Kort BJ, de Jong GJ, Somsen GW. Profiling of erythropoietin products by capillary electrophoresis with native fluorescence detection. Electrophoresis 2012;33:2996-3001.
6.	Mechref Y. Analysis of glycans derived from glycoconjugates by capillary electrophoresis-mass spectrometry. Electrophoresis 2011;32:3467-81.
7.	Reichel C, Thevis M. Gel electrophoretic methods for the analysis of biosimilar pharmaceuticals using the example of recombinant erythropoietin. Bioanalysis 2013;5:587-602.
8.	Staub A, Guillarme D, Schappler J, Veuthey JL, Rudaz S. Intact protein analysis in the biopharmaceutical field. J Pharm Biomed Anal 2011;55:810-22.
9.	Watson E, Bhide A, van Halbeek H. Structure determination of the intact major sialylated oligosaccharide chains of recombinant human erythropoietin expressed in Chinese hamster ovary cells. Glycobiology 1994;4:227-37.
10.	Solá RJ, Griebenow K. Effects of glycosylation on the stability of protein pharmaceuticals. J Pharm Sci 2008;98:1223-45.
11.	Jensen PH, Karlsson NG, Kolarich D, Packer NH. Structural analysis of N-and O-glycans released from glycoproteins. Nat Protoc 2012;7:1299-310.
12.	Zhong X, Wright JF. Biological insights into therapeutic protein modifications throughout trafficking and their biopharmaceutical applications. Int J Cell Biol 2013;2013:273086.
13.	Goh JS, Liu Y, Liu H, Chan KF, Wan C, Teo G, et al. Highly sialylated recombinant human erythropoietin production in large-scale perfusion bioreactor utilizing CHO-gmt4 (JW152) with restored GnT I function. Biotechnol J 2014;9:100-9.
14.	Arakawa T, Prestrelski SJ, Kenney WC, Carpenter JF. Factors affecting short-term and long-term stabilities of proteins. Adv Drug Deliv Rev 2001;46:307-26.
15.	Cromwell ME, Hilario E, Jacobson F. Protein aggregation and bioprocessing. AAPS J 2006;8:E572-9.
16.	Jenkins N. Modifications of therapeutic proteins: Challenges and prospects. Cytotechnology 2007;53:121-5.
17.	Korotchkina LG, Ramani K, Balu-Iyer SV. Folding considerations for therapeutic protein formulations. Prog Mol Biol Transl Sci 2008;83:255-70.
18.	Krishnamurthy R, Manning MC. The stability factor: Importance in formulation development. Curr Pharm Biotechnol 2002;3:361-71.
19.	Liu DT. Glycoprotein pharmaceuticals: Scientific and regulatory considerations, and the US Orphan Drug Act. Trends Biotechnol 1992;10:114-20.
20.	Luo Y, Matejic T, Ng CK, Rouse J, Shang T, Steckert J. Characterization and analysis of biopharmaceutical proteins. In: Ahuja S, Scypinski S, editors. Handbook of Modern Pharmaceutical Analysis. San Diego, CA: Academic Press; 2010. p. 283.
21.	Volkin DB, Mach H, Middaugh CR. Degradative covalent reactions important to protein stability. Mol Biotechnol 1997;8:105-22.
22.	Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int J Pharm 1999;185:129-88.
23.	Xie M, Schowen RL. Secondary structure and protein deamidation. J Pharm Sci 1999;88:8-13.
24.	Moya G, Yanet T, Rodríguez EN, González LJ, Besada V. Caracterización del mapa tríptico de la eritropoyetina humana recombinante por espectrometría de masas. Biotechnol Apl 2003;20:6.
25.	Cai XY, Wake A, Gouty D. Analytical and bioanalytical assay challenges to support comparability studies for biosimilar drug development. Bioanalysis 2013;5:517-20.
26.	Peptide mapping by reversed-phase high performance chromatography: Application note 99. In: Corporation D, editor. Application Note. Dionex Corporation; 1994. p. 6.
27.	Alsenaidy MA, Jain NK, Kim JH, Middaugh CR, Volkin DB. Protein comparability assessments and potential applicability of high throughput biophysical methods and data visualization tools to compare physical stability profiles. Front Pharmacol 2014;5:39.
28.	Chuan KH, Lim SF, Martin L, Yun CY, Loh SO, Lasne F, et al. Caspase activation, sialidase release and changes in sialylation pattern of recombinant human erythropoietin produced by CHO cells in batch and fed-batch cultures. Cytotechnology 2006;51:67-79.
29.	Erslev A. Erythropoietin coming of age. N Engl J Med 1987;316:101-3.
30.	Martínez-Ceron MC, Marani MM, Taulés M, Etcheverrigaray M, Albericio F, Cascone O, et al. Affinity chromatography based on a combinatorial strategy for rerythropoietin purification. ACS Comb Sci 2011;13:251-8.
31.	Chen FT, Dobashi TS, Evangelista RA. Quantitative analysis of sugar constituents of glycoproteins by capillary electrophoresis. Glycobiology 1998;8:1045-52.
32.	Elliott P, Hohmann A, Spanos J. Protease expression in the supernatant of chinese hamster ovary cells grown in serum-free culture. Biotechnol Lett 2003;25:1949-52.
33.	Jelkmann W. Erythropoietin: Structure, control of production, and function. Physiol Rev 1992;72:449-89.
34.	Llop E, Gutiérrez-Gallego R, Segura J, Mallorquí J, Pascual JA. Structural analysis of the glycosylation of gene-activated erythropoietin (epoetin delta, Dynepo). Anal Biochem 2008;383:243-54.
35.	Yang M, Butler M. Enhanced erythropoietin heterogeneity in a CHO culture is caused by proteolytic degradation and can be eliminated by a high glutamine level. Cytotechnology 2000;34:83-99.
36.	Bones J, McLoughlin N, Hilliard M, Wynne K, Karger BL, Rudd PM. 2D-LC analysis of BRP 3 erythropoietin N-glycosylation using anion exchange fractionation and hydrophilic interaction UPLC reveals long poly-N-acetyl lactosamine extensions. Anal Chem 2011;83:4154-62.
37.	Sinclair AM, Elliott S. Glycoengineering: The effect of glycosylation on the properties of therapeutic proteins. J Pharm Sci 2005;94:1626-35.
38.	Takeuchi M, Takasaki S, Shimada M, Kobata A. Role of sugar chains in the in vitro biological activity of human erythropoietin produced in recombinant Chinese hamster ovary cells. J Biol Chem 1990;265:12127-30.
39.	Narhi LO, Arakawa T, Aoki KH, Elmore R, Rohde MF, Boone T, et al. The effect of carbohydrate on the structure and stability of erythropoietin. J Biol Chem 1991;266:23022-6.
40.	Uchida E, Morimoto K, Kawasaki N, Izaki Y, Abdu Said A, Hayakawa T. Effect of active oxygen radicals on protein and carbohydrate moieties of recombinant human erythropoietin. Free Radic Res 1997;27:311-23.
41.	Shental-Bechor D, Levy Y. Effect of glycosylation on protein folding: A close look at thermodynamic stabilization. Proc Natl Acad Sci U S A 2008;105:8256-61.
42.	Tsuda E, Kawanishi G, Ueda M, Masuda S, Sasaki R. The role of carbohydrate in recombinant human erythropoietin. Eur J Biochem 2005;188:405-11.
43.	Endo Y, Nagai H, Watanabe Y, Ochi K, Takagi T. Heat-induced aggregation of recombinant erythropoietin in the intact and deglycosylated states as monitored by gel permeation chromatography combined with a low-angle laser light scattering technique. J Biochem 1992;112:700-6.
44.	Goldwasser E, Kung CK, Eliason J. On the mechanism of erythropoietin-induced differentiation. 13. The role of sialic acid in erythropoietin action. J Biol Chem 1974;249:4202-6.
45.	Melmer M. Investigation of High-Performance Liquid Chromatography Methods for the Analysis of Protein N-glycans. Uniwien University; 2010.
46.	Freeze HH. Use of glycosidases to study protein trafficking. In: Current Protocols in Cell Biology. New York City: Wiley Online Library; 2001. p. 15.2. 1-.2. 26.
47.	Walsh G, Jefferis R. Post-translational modifications in the context of therapeutic proteins. Nat Biotechnol 2006;24:1241-52.
48.	Sepahi M, Kaghazian H, Sereshkeh MP, Sadeghcheh T, Hadadian S, Jebeli MR, et al. Optimization of Dynamic Binding Capacity of Anion Exchange Chromatography Media for Recombinant Erythropoietin Purification. Iran J Biotech 2014;12:e17352.
49.	Manzi A. Acid hydrolysis for release of monosaccharides. Curr Protoc Mol Biol 2001;Chapter 17:Unit17.16.
50.	Office BPC. Erythropoietin Concentrated Solution. British Pharmacopoeia London: The Stationery Office on behalf of the Medicines and Healthcare Products Regulatory Agency (MHRA). 2012. p. 4-5.
51.	Gallagher SR. Overview of Electrophoresis. Current Protocols Essential Laboratory Techniques; John Wiley and Sons Inc.; 2008. p. 7.1.1- 7.1.7.
52.	Rosenberg LM. Identification of the Target Protein. Protein Analysis and Purification Benchtop. Boston: Brikhauser; 2005. p. 231-32.
53.	Zhu A, Martosella J, Duong PT. Peptide Mapping of Glycoprotein Erythropoietin by HILIC LC-MS and RPLC- MS. 2013.

Advanced Biomedical Research